The combined use of intravenous and oral calcium for the treatment of vitamin D dependent rickets type II (VDDRII)
- PMID: 8396512
- DOI: 10.1111/j.1365-2265.1993.tb01779.x
The combined use of intravenous and oral calcium for the treatment of vitamin D dependent rickets type II (VDDRII)
Abstract
Objective: Some patients with rickets are resistant to vitamin D and its analogues; we therefore assessed whether or not normal mineralization could be achieved in the absence of an intact 1,25(OH)2D3 receptor-effector system, by the use of intravenous high dose calcium infusion, followed by high dose oral calcium.
Design: We studied two patients with vitamin D dependent rickets type II and with absent responses to either high dose calcitriol or to oral calcium alone. Daily infusions equivalent to up to 1.4 g elemental calcium supplemented with oral phosphate were given for a period of 3.5 months for the elder sister and 2 months in the younger brother. Both patients were then treated by weekly calcium infusions for 5 months, followed by maintenance on oral calcium equivalent to up to 6 g elemental calcium per day.
Patients: Two siblings of consanguineous parents, a girl aged 28 months and a boy aged 10 months with vitamin D dependent rickets type II.
Measurements: Measurements of serum and urine calcium, phosphate and serum alkaline phosphatase were obtained before, during and after the calcium infusions. Twenty-four-hour urinary minerals, electrolytes, creatinine clearance, serum PTH and vitamin D metabolites were measured prior to calcium infusion, then repeated at 2-monthly intervals. Glomerular filtration rate, kidney ultrasound and CT scan were done at 6-monthly intervals. A scalp biopsy was done at the end of i.v. calcium treatment.
Results: The daily infusions of calcium supplemented with oral phosphate resulted in biochemical responses with normalization of calcium and phosphate in 3-5 days, and of alkaline phosphatase and PTH in 1.5-2 months. Radiological evidence of healing was seen in 42 days. A total of 3.5 months of daily calcium infusion in the elder sister and 2 months in the younger brother resulted in complete healing biochemically and radiologically, with improvement in height. The patients are under current follow-up, with no evidence of nephrocalcinosis or deterioration of glomerular filtration rate.
Conclusions: (a) The use of intravenous high dose calcium infusions followed by high dose oral calcium is an effective method of treatment of vitamin D dependent rickets type II. (b) The treatment was more effective since it was started early in the course of the disease and led to early healing and better growth with prevention of bone deformities. (c) Early treatment may also lead to improvement in alopecia, the mechanism for which needs to be elucidated.
Abbreviations: 1,25(OH)2D3, 1,25-dihydroxyvitamin D3 (calcitriol); 24-OHase, 25-(OH)D(3),24-hydroxylase; 1 alpha-(OH)D3, 1 alpha-hydroxyvitamin D3; 25(OH)D3, 25-hydroxyvitamin D3; 1 alpha-OHase, 1 alpha-hydroxylase; PTH, parathyroid hormone.
Similar articles
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
-
Long-term intracaval calcium infusion therapy in end-organ resistance to 1,25-dihydroxyvitamin D.Am J Med. 1987 Nov;83(5):984-90. doi: 10.1016/0002-9343(87)90666-8. Am J Med. 1987. PMID: 2823606
-
The role of the vitamin D receptor in regulating vitamin D metabolism: a study of vitamin D-dependent rickets, type II.J Clin Endocrinol Metab. 2001 May;86(5):1908-12. doi: 10.1210/jcem.86.5.7448. J Clin Endocrinol Metab. 2001. PMID: 11344183
-
Oral calcium treatment in vitamin D-dependent rickets type II.J Paediatr Child Health. 1994 Oct;30(5):444-6. doi: 10.1111/j.1440-1754.1994.tb00699.x. J Paediatr Child Health. 1994. PMID: 7833085
-
Recent advances in pediatric metabolic bone disease: the consequences of altered phosphate homeostasis in renal insufficiency and hypophosphatemic vitamin D-resistant rickets.Bone Miner. 1990 Jun;9(3):199-214. doi: 10.1016/0169-6009(90)90038-h. Bone Miner. 1990. PMID: 2163713 Review.
Cited by
-
Genotypic Spectrum and its Correlation with Alopecia and Clinical Response in Hereditary Vitamin D Resistant Rickets: Our Experience and Systematic Review.Calcif Tissue Int. 2023 Apr;112(4):483-492. doi: 10.1007/s00223-023-01061-8. Epub 2023 Jan 27. Calcif Tissue Int. 2023. PMID: 36705686
-
New developments in our understanding of vitamin metabolism, action and treatment.Metabolism. 2019 Sep;98:112-120. doi: 10.1016/j.metabol.2019.06.010. Epub 2019 Jun 19. Metabolism. 2019. PMID: 31226354 Free PMC article. Review.
-
Genetic Causes of Rickets.J Clin Res Pediatr Endocrinol. 2017 Dec 30;9(Suppl 2):88-105. doi: 10.4274/jcrpe.2017.S008. Epub 2017 Dec 27. J Clin Res Pediatr Endocrinol. 2017. PMID: 29280738 Free PMC article. Review.
-
Vitamin D and bone.Curr Osteoporos Rep. 2012 Jun;10(2):151-9. doi: 10.1007/s11914-012-0098-z. Curr Osteoporos Rep. 2012. PMID: 22544628 Free PMC article. Review.
-
Persistent Hyperparathyroidism in Vitamin D-Dependent Rickets Type 2A Does Not Prevent Normalization of Hypophosphatemia or Healing of the Rickets.Horm Res Paediatr. 2025 May 16:1-10. doi: 10.1159/000546444. Online ahead of print. Horm Res Paediatr. 2025. PMID: 40383122 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources